Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,922.00 | 4.90 | 0.05% |
CAC 40 | 7,617.63 | 71.47 | 0.95% |
DAX 40 | 23,738.44 | 312.47 | 1.33% |
Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
FTSE 100 | 9,112.92 | 44.34 | 0.49% |
HKSE | 24,733.45 | 225.64 | 0.92% |
NASDAQ | 20,650.13 | 472.31 | -2.24% |
Nikkei 225 | 40,290.70 | 508.90 | -1.25% |
NZX 50 Index | 12,684.04 | 45.36 | -0.36% |
S&P 500 | 6,238.01 | 101.38 | -1.60% |
S&P/ASX 200 | 8,663.70 | 1.70 | 0.02% |
SSE Composite Index | 3,583.31 | 23.36 | 0.66% |